drugset / Trial / NCT03753269

Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

NCT03753269

Phase 4 Unknown 600 enrolled RenJi Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The study aims to evaluate whether an early intracoronary administration of Fasudil Hydrochloride during primary PCI of STEMI can improve epicardial and myocardial perfusion as well as clinical outcomes.

Timeline

Start
2019-07-01
Primary completion
2022-06-30
Completion
2022-12-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasudil Small molecule 2.5 mg Other